- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
- Interventions
- OMS721 (narsoplimab)
- Biological
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Crovalimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 28 Days to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Crovalimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
- Conditions
- Mucositis, Graft-versus-host Disease
- Interventions
- Tac+MTX, TAC + MMF
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2031
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Fort Wayne, Indiana • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
- Conditions
- Acute Renal Failure, Chronic Kidney Failure, Endothelial Dysfunction, Hemolytic-uremic Syndrome (HUS)
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
- Conditions
- Thrombotic Microangiopathies
- Interventions
- OMS721
- Biological
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Eculizumab
- Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Hairy Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Pueblo, Colorado • Bridgeton, Missouri
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 12
- States / cities
- Dunwoody, Georgia • Chicago, Illinois • Portland, Maine + 9 more
- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Corpus Christi, Texas + 1 more
- Conditions
- Hemolytic Uremic Syndrome
- Interventions
- SYNSORB Pk, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 26
- States / cities
- Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 11 more
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Ravulizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Hollywood, Florida • Atlanta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Atypical Hemolytic-Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Burlington, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more